Kyongbo Pharmaceutical Co Ltd (214390) — Cash Flow Reinvestment Rate
Kyongbo Pharmaceutical Co Ltd (214390) has a Cash Flow Reinvestment Rate of 3.78x as of September 2025, reinvesting ₩17.04 Billion (capex ₩17.04 Billion ) from operating cash flow of ₩4.51 Billion. Check Kyongbo Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Kyongbo Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2014–2024)
Historical reinvestment intensity for Kyongbo Pharmaceutical Co Ltd across 10 annual periods. Explore Kyongbo Pharmaceutical Co Ltd (214390) investment intensity to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Kyongbo Pharmaceutical Co Ltd (2014–2024)
Year-by-year capital reinvestment analysis for Kyongbo Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Kyongbo Pharmaceutical Co Ltd market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 95.93x | ₩14.31 Billion | ₩149.12 Million | ₩13.18 Billion | ▲ +3205.3% |
| 2023 | 2.90x | ₩14.06 Billion | ₩4.84 Billion | ₩10.88 Billion | ▲ +4.7% |
| 2022 | 2.77x | ₩28.06 Billion | ₩10.13 Billion | ₩13.18 Billion | ▲ +143.5% |
| 2021 | 1.14x | ₩20.45 Billion | ₩17.97 Billion | ₩18.32 Billion | ▲ +20.5% |
| 2020 | 0.94x | ₩19.63 Billion | ₩20.80 Billion | ₩12.44 Billion | ▼ -18.6% |
| 2019 | 1.16x | ₩27.45 Billion | ₩23.67 Billion | ₩23.25 Billion | ▲ +256.4% |
| 2017 | 0.33x | ₩8.40 Billion | ₩25.81 Billion | ₩7.40 Billion | ▼ -79.3% |
| 2016 | 1.57x | ₩39.84 Billion | ₩25.33 Billion | ₩19.68 Billion | ▼ -76.0% |
| 2015 | 6.56x | ₩27.80 Billion | ₩4.24 Billion | ₩27.26 Billion | ▲ +423.9% |
| 2014 | 1.25x | ₩20.08 Billion | ₩16.04 Billion | ₩19.28 Billion | — |